This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Breast-Sparing Proton Therapy for Hodgkin's Disease (Breast Sparing)

This study has been terminated.
(Closure of Indiana University Health Proton Center in December 2014)
Sponsor:
Information provided by (Responsible Party):
Indiana University
ClinicalTrials.gov Identifier:
NCT02070393
First received: April 19, 2012
Last updated: February 3, 2015
Last verified: February 2015
  Purpose
The purpose of this study is to drastically reduce unnecessary breast dose in young females with Hodgkin's Disease who require radiation therapy.

Condition Intervention Phase
Hodgkins Disease Radiation: Proton Early Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Treatment
Official Title: Breast-Sparing Proton Therapy for Hodgkin's Disease in Young Females Demonstrated By Positron Emission Tomograpy (PET) Scanning: A Pilot Study

Resource links provided by NLM:


Further study details as provided by Indiana University:

Primary Outcome Measures:
  • Comparative DVH data for delivered proton plan and accompanying photon plan for target volume and normal tissues. [ Time Frame: 12 months ]

    Dose-volume histogram data from both the delivered proton plan and the accompanying photon plan for target volumes and normal tissues, including:

    • Breast, heart, lung, thyroid, parotid glands , esophagus, spinal cord, *liver, *kidneys,



Secondary Outcome Measures:
  • Treatment toxicity and disease control of proton therapy for the treatment of pediatric Hodgkin's Lymphoma. [ Time Frame: 3 - 60 Months ]
    1. Acute toxicity as per CTCAE v4.0
    2. Local, regional, and distal control of the disease at 3 years


Enrollment: 3
Study Start Date: September 2011
Study Completion Date: February 2015
Primary Completion Date: February 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Radiation Treatment using Protons
14 -24 Radiation Treatments (typically 1.5 - 1.8 cobalt-Gray equivalent per fraction for 14-24 treatments).
Radiation: Proton
14-24 Radiation treatments using Protons
Other Name: Breast sparing using proton beams

Detailed Description:

According to the National Cancer Institute's Surveillance, Epidemiology, and End Results Program, there will be an estimated 8,490 new cases of Hodgkin's Lymphoma (HL) in the United States in 2010, with an estimated 1,320 deaths (Jemal, Siegel et al.). The unadjusted rates of 5 year overall survival are approximately 95%, and remain among the highest of all childhood and adult malignancies. With many children and young adults surviving into advanced age, the impetus has been to develop less toxic yet equally effective treatments. One of the main approaches taken over the last 25 years to minimize long-term treatment toxicity has been to limit the amount and volume of radiation received by patients. This pilot study continues along those lines, attempting to further refine the delivery of radiation therapy (RT) in order to avoid one of the most notorious long-term side-effects: secondary breast cancer.

Multiple studies investigating late toxicity in long-term survivors of pediatric Hodgkin's Lymphoma have shown the risk of breast cancer in young females receiving mediastinal radiation to be 50 times greater than their age-matched counterparts. The Late Effects Study Group, with a median follow-up of 17 years, reported a breast cancer incidence of 16% with a standardized incidence ratio of 55.5 (Bhatia, Yasui et al. 2003). Through utilization of breast-sparing proton therapy, we hope to provide young female patients with the benefits of radiation therapy while decreasing their risk of secondary breast cancer, thus increasing the therapeutic ratio.

In a prior computer-based, in-silico, dose planning study, utilizing the most basic beam orientation (a single PA beam), we showed that dose to breast tissue was reduced by a minimum of at least 80% with proton treatment compared to standard AP-PA photon treatment (in publication). Furthermore, dose to clinical target volume was maintained, and dose to other normal structures was statistically no worse. We now aim to validate these findings by verifying the beam range, in-vivo, via post-treatment combined Positron Emission Tomography-Computer Tomography (PET-CT) imaging in young females undergoing supra-diaphragmatic radiotherapy for Hodgkin's Disease.

  Eligibility

Ages Eligible for Study:   10 Years to 30 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Female sex
  • Age >/= 10 years old and < 30 years old
  • Pathologically confirmed classical Hodgkin's Lymphoma
  • At least one site of disease located above the diaphragm
  • Signed study-specific consent prior to initiation of therapy
  • Women of child-bearing potential must have a negative pregnancy blood test within 7 days of starting protocol therapy.

Exclusion Criteria:

  • Previous radiation therapy to any part of the body.
  • Parenchymal lung involvement at initial presentation or any patient that may need whole lung irradiation as per institutional guidelines.
  • Lymphocyte predominant histology not eligible.
  • Significant infection or other coexistent medical condition that would preclude protocol therapy such as:

    • History of HIV/AIDS
    • History of collagen Vascular Disease
    • Symptomatic congestive heart failure
    • Unstable angina pectoris or myocardial infarction within 6 months
    • Uncontrolled hypertension (systolic blood pressure > 160 mm Hg or diastolic blood pressure > 100 mm Hg on 2 consecutive measurements separated by 1 week).
    • History of uncontrolled diabetes
    • Psychiatric illness/social situations that would compromise patient safety or limit compliance with study requirements
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02070393

Locations
United States, Indiana
Indiana University Health Proton Therapy Center
Bloomington, Indiana, United States, 47408
Sponsors and Collaborators
Indiana University
Investigators
Principal Investigator: Jeffery Buchsbuam, MD Indiana University
  More Information

Responsible Party: Indiana University
ClinicalTrials.gov Identifier: NCT02070393     History of Changes
Other Study ID Numbers: IUHPTC-01
Study First Received: April 19, 2012
Last Updated: February 3, 2015

Keywords provided by Indiana University:
Hodgkins Disease in Young Females
Breast Sparing Radiation Treatments

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on July 24, 2017